1-Iodo-3,5-dimethylbenzene | CAS:22445-41-6

We serve 1-Iodo-3,5-dimethylbenzene CAS:22445-41-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Iodo-3,5-dimethylbenzene

Chemical Name:1-Iodo-3,5-dimethylbenzene
CAS.NO:22445-41-6
Synonyms:1-Iodo-3,5-dimethylbenzene
1,3-dimethyl-5-iodobenzene
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 229.9±9.0 °C at 760 mmHg
Molecular Formula C8H9I
Molecular Weight 232.061
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.593
 
Specification:
Appearance:Pink-brown to red transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 1-Iodo-3,5-dimethylbenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-dimethyl-5-iodobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3-dimethyl-5-iodobenzene Use and application,1-Iodo-3,5-dimethylbenzene technical grade,usp/ep/jp grade.


Related News: Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).N,N'-Bis(benzyloxycarbonyl)-L-cystine manufacturer When a new strain emerges that has not yet been identified, as is the case with the current outbreak in China, it temporarily becomes known as a novel coronavirus (nCoV).3-(Trifluoromethoxy)bromobenzene supplier When a new strain emerges that has not yet been identified, as is the case with the current outbreak in China, it temporarily becomes known as a novel coronavirus (nCoV).2-Bromo-4-butanolide vendor The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.Judging from the geographical distribution of enterprises, the largest distribution of API companies is Jiangsu and Zhejiang, with more than 300 enterprises; followed by Shandong, Sichuan and Hubei.